All the usual good stuff in there. Vitiligo to complete and results next year and that exciting potential figure again of $490 - $570 Million USD in years 1-2. A lot of near term growth just for EPP, eg dosage expansion for adults EMA, children EMA re -file, Canada decision, US treatment centre growth etc. Also the big "will become a household name" statement. Also $20 Million for a 12 month share buyback. Just do the bloody buyback, it will make a real difference for shareholders by buying and deleting 1.5 Million CUV shares when there are only 50 Million on issue. We can all see how just a relatively small amount of buying has changed the share price to benefit shareholders. The weird thing is they could have completed the entire share buyback for just $15 Million or $16 Million in recent months when it was getting massively manipulated by shorters. Either way just do the buyback and stop just talking about it while awarding shares to yourselves - there will never be an acquisition as good as Clinuvel are now: ie printing cash at growing rates, $200 Million cash growing all the time, blockbuster phase 3 about to complete with already FDA approved drug, proven growth, proven low cost distribution network and mega cosmetic opportunities with a unique and real tanning photocosmetic they have announced in Bulletin 2.
All IMO DYOR
CUV Price at posting:
$13.04 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)